Q-omics provides the consensus-scored SUCLG1 profile across patient tissues and cancer cell-line models. SUCLG1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SUCLG1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SUCLG1 protein abundance shows 24,230 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRC, and GBM as cancer lineages where SUCLG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUCLG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUCLG1 survival associations across molecular data types. SUCLG1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUCLG1 RNA expression–survival associations across cancer types. High SUCLG1 expression shows unfavorable associations in UCEC and LIHC, but favorable associations in READ, KIRC, COAD and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SUCLG1 RNA expression.
This table summarizes SUCLG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SUCLG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUCLG1 shows lower tumor expression in KIRC, KIRP, THCA, COAD, KICH and BRCA. The KIRC box plot shows higher SUCLG1 RNA expression in normal versus tumor tissue (log2 FC = −1.580, t-test p < 0.001).
This table shows molecular features associated with SUCLG1 in patient tissues and cancer cell lines. In patient samples, SUCLG1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SUCLG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
